MRK vs NEO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NeoGenomics exhibits a stable financial foundation with a Piotroski F-Score of 5/9 and exceptional liquidity (Current Ratio 4.26), though it remains unprofitable with a -14.85% profit margin. While the company has a remarkable track record of beating earnings estimates and shows positive YoY EPS growth, this is offset by a disastrous 5-year price decline of 83.1% and bearish insider activity. The stock appears undervalued relative to analyst targets ($14.81), but the lack of current profitability and negative technical trends suggest a speculative recovery play rather than a value certainty.
Compare Another Pair
Related Comparisons
MRK vs NEO: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and NeoGenomics, Inc. (NEO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.